Data: Approximately 76,100 SOL flowed into a certain exchange's Prime, valued at about $6.49 million.

Biotechnology giant Moderna recently disclosed that the company expects to recognize an expense of up to $950 million in its financial statements for the first quarter of 2026.

Roivant Sciences Ltd. (ROIV) announced that its board of directors has officially approved a stock buyback plan totaling up to 1 billion dollars.

Vertiv (Vertiv Holdings LLC) recently announced the successful completion of two key financing transactions: a $2.1 billion senior unsecured bond issuance and a $2.5 billion senior unsecured revolving credit facility.

The biopharmaceutical company Arbutus Biopharma Corporation (ABUS), a subsidiary of Roivant Sciences Ltd. (ROIV), is currently actively evaluating a capital return plan.